PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Alimemazine tartrate - Pruritis in eczema

PAD Profile : Alimemazine tartrate - Pruritis in eczema

Keywords :
trimeprazine, sedating antihistamines
Brand Names Include :
Valergan, Itzenal

Traffic Light Status

Status 1 of 2.

Status :
Black
Formulations :
  • Not Specified
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Status 2 of 2.

Status :
See narrative
Formulations :
  • Not Specified
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

No drugs returned.

Other Indications

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
03 June 2020
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

At the Surrey and North-West Sussex Area Prescribing Committee (APC) held in June 2020, it was decided that all BLACK status drugs would have their review dates extended for 5 years without the need for a review.

If a clinician or provider wishes to change the traffic light status of any BLACK drug then they will need to submit a paper for change as per usual APC process.

06 December 2017
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
The PCN does not recommend alimemazine (trimeprazine) for the treatment of pruritis in eczema. Alimemazine (trimeprazine) will be considered BLACK on the traffic light system for new patients Patients whose treatment with alimemazine was initiated by the NHS before this recommendation was made, must be reviewed by their NHS consultant within 12 months but, should be able to continue treatment until the patient and their NHS consultant consider it appropriate to stop.

Associated BNF Codes

03. Respiratory System
03.04.01. Antihistamines
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More